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Avoidance and its perseveration represent key features of anxiety disorders. Both
pharmacological and behavioral approaches (i.e., anxiolytics and extinction therapy) have
been utilized to modulate avoidance behavior in patients. However, the outcome has not
always been desirable. Part of the reason is attributed to the diverse neuropathology of
anxiety disorders. Here, we investigated the effect of psychotropic drugs that target vari-
ous monoamine systems on extinction of avoidance behavior using lever-press avoidance
task. Here, we used the Wistar-Kyoto (WKY) rat, a unique rat model that exhibits facilitated
avoidance and extinction resistance along with malfunction of the dopamine (DA) system.
Sprague Dawley (SD) and WKY rats were trained to acquire lever-press avoidance. WKY
rats acquired avoidance faster and to a higher level compared to SD rats. During phar-
macological treatment, bupropion and desipramine (DES) significantly reduced avoidance
response selectively in WKY rats. However, after the discontinuation of drug treatment,
only those WKY rats that were previously treated with DES exhibited lower avoidance
response compared to the control group. In contrast, none of the psychotropic drugs facil-
itated avoidance extinction in SD rats. Instead, DES impaired avoidance extinction and
increased non-reinforced response in SD rats. Interestingly, paroxetine, a widely used anti-
depressant and anxiolytic, exhibited the weakest effect in WKY rats and no effects at all
in SD rats. Thus, our data suggest that malfunctions in brain catecholamine system could
be one of the underlying etiologies of anxiety-like behavior, particularly avoidance persever-
ation. Furthermore, pharmacological manipulation targeting DA and norepinephrine may
be more effective to facilitate extinction learning in this strain. The data from the present
study may shed light on new pharmacological approaches to treat patients with anxiety
disorders who are not responding to serotonin re-uptake inhibitors.
Keywords: avoidance perseveration, anxiolytic, behavioral inhibition, dopamine, norepinephrine, serotonin,
transporter inhibitors
INTRODUCTION
Anxiety disorders are the most common psychiatric disorder with
a lifetime prevalence of over 15% in the U.S. (Kessler et al., 2005;
Somers et al., 2006). Although the etiopathology of anxiety dis-
orders remains elusive, the core characteristic of all anxiety disor-
ders is pathological avoidance (American Psychiatric Association,
2000). Compared to normal strategic avoidance, psychopatholog-
ical avoidance is hypersensitive to stimuli, resistant to extinction,
and often results in poor productivity and inefficiency that hinder
daily activity (Beck et al., 2010; Berman et al., 2010). However, ther-
apies targeting pathological avoidance are quite underdeveloped
and problematic for people suffering clinical anxiety.
Current treatment for anxiety disorder includes psychologi-
cal [i.e., cognitive behavioral therapy (CBT)], pharmacological
approaches, and the combination of both. Extinction-resistant
avoidance is one of the target symptoms in CBT, which is largely
based on changing behavior through different learning approaches
(Holmes and Quirk, 2010; Nic Dhonnchadha and Kantak, 2011;
Schneier, 2011; Melo et al., 2012). Clinical evidence shows that
combined approaches yield the highest success rate compared to
each approach alone [for review, see Pollack et al. (2008)]. Among
the Food and Drug Administration (FDA) approved anxiolytic
agents, selective serotonin re-uptake inhibitors (SSRIs) are the
drugs of first choice due to their mild side effects allowing for
better compliance in patients. However, a large group of patients
do not respond to SSRI treatment (>40%) or relapse after initial
effective treatment (Pollack et al., 2006, 2008), providing a need
for new therapeutic agents and strategies for refractory cases.
A better understanding of the neuropathology of core anxiety
symptoms is essential for developing more effective treatments.
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We recently described a rat model of anxiety-like behavior, the
Wistar-Kyoto (WKY) rat (Servatius et al., 2008; Jiao et al., 2011b).
This inbred rat strain differs from normal outbred strains, such
as Sprague Dawley (SD) rats, in avoidance propensity and per-
severation and neuronal activity in brain regions critical for fear
learning and anxiety (Beck et al., 2011; Jiao et al., 2011b). The WKY
strain also exhibits behavioral inhibition temperament in the face
of social and non-social stressful stimuli, heightened physiolog-
ical and neuroendocrine responsiveness to stressful stimuli, and
negative bias toward external cues, indicating greater anxiety vul-
nerability compared to normal outbred strains (Athey and Iams,
1981; Pare, 1992a,b; Redei et al., 1994; Lopez-Rubalcava and Lucki,
2000).
Although the exact mechanism for the altered behavior of
the WKY rats is not well understood, much focus has been
directed toward malfunction of central monoaminergic systems.
The WKY rat exhibits altered dopamine (DA) and norepineph-
rine (NE) receptors and transporter levels in cortical and sub-
cortical regions compared to SD and Wistar (WIS) rats (Jiao
et al., 2011b). Pharmacological studies demonstrate that repeated
treatment with drugs that enhance catecholaminergic transmis-
sion reverses abnormal behavior in WKY but not in outbred rats
(Pare et al., 2001; Tejani-Butt et al., 2003). For instance, bupropion
(BUP) [dopamine transporter (DAT) inhibitor] increases locomo-
tion in the open field test (OFT), while nomifensine [DAT and
norepinephrine transporter (NET) inhibitor] and desipramine
(DES) (tricyclic antidepressant that mainly block NET) facilitate
OFT activity and swimming behavior in the Forced Swim Test
(FST) of WKY rats (Pare et al., 2001; Tejani-Butt et al., 2003). How-
ever, neither fluoxetine nor paroxetine (PAR) (selective serotonin
transporter inhibitors, SSRIs) are effective on similar behaviors
(Durand et al., 1999; Lopez-Rubalcava and Lucki, 2000; Tejani-
Butt et al., 2003). The data suggest that anxiety-like symptoms in
WKY rats are SSRI-resistant but may be modified by psychotropic
drugs acting on NE and/or DA (Lahmame et al., 1997; Tejani-Butt
et al., 2003).
In the present study, we compared the effects of monoaminer-
gic transporter inhibitors on avoidance extinction in SD and WKY
rats. We predicted that NET and DAT inhibitors but not SSRI
would facilitate avoidance extinction and reduce active-avoidance
behavior selectively in WKY rats.
MATERIALS AND METHODS
ANIMALS
Forty male SD (body weight= 321± 2.8 g) and 40 male WKY
(body weight= 239± 1.8 g) rats (approximately 60 days of age at
the start of the experiment) were obtained from Harlan Sprague-
Dawley Laboratories (Indianapolis, IN, USA). Rats were housed
in individual cages with free access to food and water in a room
maintained on a 12:12 h day/night cycle for 2 weeks prior to exper-
imentation. Experiments occurred between 07:00 and 15:00 h in
the light portion of the cycle. One WKY rat treated with DES was
eliminated from the study due to significant weight loss in the last
three extinction sessions. All procedures received prior approval
by the Institutional Animal Care and Use Committee at the VA
New Jersey Health Care System and were conducted in accordance
with the NIH Guide for the Care and Use of Laboratory Animals.
LEVER-PRESS ESCAPE/AVOIDANCE TRAINING
The apparatus was described previously (Servatius et al., 2008).
Training was conducted in 16 identical operant chambers (Coul-
bourn Instruments, Langhorn, PA, USA). Each operant chamber
was enclosed in a sound-attenuated box. Scrambled 2.0-mA foot-
shocks were delivered through the grid floor (Coulbourn Instru-
ments, Langhorn, PA, USA). Despite an increased sensitivity to
stress in WKY rats, WY, and SD rats exhibited a similar threshold
to vocalize in response to foot-shock (un-published observation),
suggesting similar pain sensitivity to foot-shocks. The auditory
warning signal was a 1000-Hz, 75-dB tone (10 dB above back-
ground noise). A 3-min intertrial interval (ITI) was explicitly
signaled with a 5-Hz blinking cue light (safety signal) located
above the lever. Graphic State Notation software (v. 3.02, Coul-
bourn Instruments, Langhorn, PA, USA) controlled the stimuli
and recorded responses.
Each session began with a 60-s stimulus-free period. A trial
commenced with the presentation of the auditory warning signal.
During avoidance acquisition training, a lever-press during the
first 60 s of the warning signal constituted an“avoidance”response,
terminated the warning signal, and triggered the ITI period. In the
absence of a lever-press in the first 60 s of the warning signal,
0.5 s foot shocks were delivered with an inter-shock interval of
3 s. A lever-press during the shock period constituted an “escape
response,” terminated the shock and warning signal and triggered
the ITI. A maximum of 100 foot-shocks could be delivered on each
trial. During avoidance extinction training, foot-shock was not
delivered and safety signal was not presented. A lever-press made
during the first 60 s of the warning signal constituted an avoid-
ance response, while the lever-press made during the rest warning
signal constituted an escape response. Both responses terminated
the warning signal and initiated a non-signaled ITI period. Each
session consisted of 20 trials. Extinction training occurred in the
same training box as acquisition learning.
DRUG ADMINISTRATION
Bupropion hydrochloride (a DAT blocker, 20 mg/ml/kg, i.p.,
Sigma-Aldrich, St Louis, MO, USA), desipramine hydrochlo-
ride (a NET blocker, 10 mg/ml/kg, i.p., Sigma-Aldrich, St Louis,
MO, USA), paroxetine hydrochloride (a SSRI, 10 mg/ml/kg, i.p.,
Toronto Research Chemicals, Toronto, ON, CA), or saline vehicle
solution (1 ml/kg, i.p.) was injected daily between 16:00 and 17:00
(after the avoidance session on days of training) to avoid acute
drug effects on behavioral testing. The dosage used was the effec-
tive dosage tested in open field and FST on WKY rat (Tejani-Butt
et al., 2003; Jiao et al., 2006).
SEQUENCE OF BEHAVIORAL PROCEDURES
Avoidance training sessions occurred three times per week (every
2–3 days). Avoidance acquisition training continued for 12 ses-
sions. After the acquisition phase, rats were administered BUP,
DES, PAR, saline (SAL) treatment, or no treatment. For each strain,
rats were stratified on avoidance performance during acquisition
session 12 (A12) and then randomly assigned within each stratum
to BUP, DES, PAR, SAL treatment, or no injection group. Rats
were treated daily from the day following the last acquisition ses-
sion (A12) to the day before the sixth extinction session (E06).
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Extinction training (absence of shock and intertrial-interval sig-
nal) began 2 weeks after the last acquisition session (session 13)
and continued for nine sessions. Therefore, the first six sessions
of extinction were with drug or SAL and the last three extinction
sessions were drug-free. Thus, extended drug effect was evaluated
in the last three drug-free sessions.
DATA ANALYSIS
Mixed design analysis of variance (ANOVA) was used to analyze
behavioral aspects of acquisition and extinction. Ratios of avoid-
ance and escape responses, lever-presses during the first minute
of each session [anticipated responses (AR)] and non-reinforced
intertrial-interval responses (ITRs) during the first, second, and
third minute ITI (ITI-1, ITI-2, and ITI-3 min) were examined in
both phases. Both between-session and within-session avoidance
responses were examined to illustrate the main effects of strain,
drug treatment, and interactions.
In the acquisition phase, two-way ANOVA with repeated mea-
sures of session and between-groups measure of strain (2× 12)
was conducted to analyze all behavioral features using Tukey-
Kramer for post hoc comparisons. Within-session avoidance
responses were examined in early (A01–04), mid (A05–08),
and late (A09–12) session-blocks with four sessions/block across
trials (2× 20).
In the extinction phase, mixed design ANOVA was used to ana-
lyze all the behavioral aspects. Analysis of rats receiving SAL injec-
tion compared to non-injection animals revealed no differences
(all F-values <1 and p-values >0.2), and so data from subjects
in these two groups were combined into one control (CTL) group
within each strain for analysis and figure illustration during extinc-
tion. A mixed ANOVA with between-subjects factors of strain and
treatment and repeated measures of session (2× 4× 9) was used
to analyze main factors of strain, treatment, session, and interac-
tions. In order to examine the immediate (i.e., when treatment was
administered) and lasting (i.e., when treatment was discontinued)
drug effects on extinction learning in each strain, the mean avoid-
ance responses were separately analyzed within the first six sessions
and the last three sessions of extinction, using two-way ANOVA
with repeated measures of session and between-groups measure of
treatment design, treatment× extinction session (4× 6 and 4× 3,
respectively). To evaluate drug effects on within-session extinc-
tion learning, within-session avoidance response was analyzed
in early (E01–03), mid (E04–06), and late (E07–09) extinction,
respectively, using strain× treatment× trial (2× 4× 20) design
with strain and treatment as between-subjects factors and trial
as a within subject factor. Post hoc analysis was conducted using
Dunnett’s test to identify interactions.
All data are expressed as means± SEM. An alpha level equal to
0.05 was used to determine significance across all analyses. Statis-





In all respects, strain differences in avoidance learning in this study
replicate what has been described previously (Servatius et al., 2008;
Beck et al., 2010, 2011). Rats from both strains emitted greater
numbers of avoidance responses as acquisition proceeded, Ses-
sion, F(11,858)= 101.8, p< 0.001 (Figure 1A). Compared to SD
rats, WKY rats acquired avoidance response to a greater extent,
strain, F(1,78)= 17.8, p< 0.001.
Within-session analysis was conducted to compare avoid-
ance responses in three-session blocks (i.e., early, mid, and late
blocks). Within-session avoidance responses are averaged across
early (A01–04), mid (A05–08), and late (A09–12) acquisition ses-
sions. The data indicate that both strains emitted more avoidance
responses in later trials of the session, Trial, F(19,1482)= 23.3
(early, sessions A01–04), 13.9 (mid, sessions A05–08), and 7.2
(late, sessions A09–12), ps< 0.001. WKY rats exhibited superior
within-session avoidance learning compared to SD rats, strain,
F(1,78)= 24.8 (early), 5.6 (mid), and 15.2 (late), ps< 0.001. Con-
sistent with our previous findings, the within-session acquisition
learning is more obvious in SD rats as WKY rats emitted simi-
lar or greater avoidance responding on the first trial of a session
compared to the last trial from the previous session, suggesting
a lack of “warm-up” that plays a pivotal role in the development
of avoidance perseveration during extinction phase in the WKY
strain (Servatius et al., 2008) (Figure 1B).
Non-reinforced response
In terms of ARs, WKY rats made more lever-presses dur-
ing the first minute of each session as compared to SD rats,
strain, F(1,78)= 4.3, p< 0.05; both strains of rats emitted more
responses as acquisition proceeded, session, F(11,858)= 18.2,
p< 0.001 (Figure 4A). The number of intertrial-interval responses
(ITRs) in the first, second, and third-minute of the ITI period
was altered as the acquisition phase proceeded, F(11,858)= 24.4
(ITI-first minute), 13.0 (ITI-second minute), and 14.5 (ITI-third
minute), ps< 0.001 (Figure 3A). Both strains of rats emitted
more ITRs in the first minute compared to the second and third
minute. ITRs differed between strains for all ITIs, strain× session,
F(11,858)= 16.3 (ITI-first minute), 11.60 (ITI-second minute),
and 15.1 (ITI-third minute), respectively, ps< 0.001; WKY rats
responding more frequently in early than late acquisition sessions,




During extinction, all rats made fewer avoidance responses as
extinction proceeded across sessions, F(8,573)= 47.96, p< 0.001
(Figure 2A). Overall, WKY rats emitted more avoidance responses
compared to SD rats, F(1,72)= 14.88, p< 0.001. Similar to our
previous findings, WKY rats without drug treatment exhib-
ited more avoidance responses compared to SD rats with-
out drug, as reflected by significant strain× treatment inter-
action, F(3,72)= 3.91, p< 0.05. In an analysis of only WKY
rats, DES treatment facilitated extinction compared to the
un-drugged (CTL) group as reflected by treatment× session,
F(24,285)= 2.01, p< 0.005, post hoc p< 0.05; in contrast, DES
treatment in SD rats enhanced avoidance responses compared to
CTL as reflected by treatment, F(3,36)= 3.48, p< 0.05, post hoc
p< 0.05.
Rats were treated with drug or SAL for the first six sessions
of extinction, and then untreated for another three sessions of
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FIGURE 1 | Avoidance response during acquisition. (A) Avoidance
lever-press responding significantly increased in both strains although
WKY rats acquired avoidance responses significantly faster and reached
greater asymptotic performance compared to SD rats. (B) Within-session
avoidance response. Both strains emitted more avoidance responses
as an acquisition session proceeded. During early, mid, and late
acquisition phases, WKY rats exhibited significantly faster within-session
avoidance acquisition compared to SD rats. SD rats emitted less
avoidance responding in the first trial of a session compared to the
last trial of a previous session; however, this phenomenon is not
evident in WKY rats. Each data point represents group mean±SEM
(n=40/strain).
extinction. In order to assess immediate drug effects and extended
drug effects on extinction learning in both strains, mean avoid-
ance responses were compared between treatment groups within
each strain for extinction sessions with treatment (E01–06) and
extinction sessions without treatment (E07–09).
Extinction sessions with treatment (E01–06)
During the first six extinction sessions, all rats reduced avoidance
response as extinction proceeded, reflected by main effect of ses-
sion, F(5,360)= 52.76, p< 0.001; WKY rats emitted more avoid-
ance responses compared to SD rats, as reflected by a main effect of
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FIGURE 2 | Avoidance response during extinction. (A) Avoidance response
decreased in both strains while WKY rats extinguished slower as compared to
SD rats in general. WKY CTL rats emitted significantly more avoidance
responses than SD CTL rats. In WKY rats, BUP treatment significantly
decreased avoidance responses during injection sessions while DES
treatment significantly reduced such responses during all extinction sessions,
compared to CTL group. In SD rats, DES treatment impaired extinction of
avoidance response compared to CTL. (B) Within-session avoidance
response. WKY rats emitted significantly more avoidance responses than SD
rats. In WKY rats, all three drugs facilitated within-session extinction in the mid
sessions compared to CTL treatment. DES treatment maintained extinction
facilitation in late sessions while no injection was administered. In contrast, in
SD rats, DES treatment trended to produce increased avoidance response in
mid and late extinction sessions compared to CTL. Each data point represents
group mean±SEM. (n=8/treatment group, 16/CTL group). Gray shade on
x -axis indicates sessions in which drugs were administered (E01–06).
strain,F(1,72)= 8.96, p< 0.005, and a strain× treatment interac-
tion, F(2,72)= 3.36, p< 0.05. In a separate analysis of WKY rats,
BUP treatment decreased avoidance responding in all extinction
sessions except E02, DES treatment decreased avoidance respond-
ing in sessions E03–06, and PAR treatment decreased avoidance
responding in the last two extinction sessions, as reflected by treat-
ment× session interaction, F(15,180)= 2.31, p< 0.01, post hoc,
ps< 0.05, suggesting all three drugs facilitated extinction when
daily treatment was administered. In an analysis of SD rats, DES
treatment led to the highest number of avoidance response among
all treatment groups; the remaining groups (i.e., BUP, PAR, and
CTL) did not differ, main effect of treatment, F(3,36)= 3.41,
p< 0.05, post hoc p< 0.05. These results suggest DES treatment is
detrimental for extinction learning in SD rats.
Extinction sessions without treatment (E07–09)
During the last three sessions of extinction when treatment was
discontinued, WKY CTL rats emitted more avoidance response
compared to SD CTL rats [strain× treatment, F(3,71)= 4.0,
p< 0.05]. In the analysis of WKY rats, DES group exhibited a trend
of less avoidance responses compared to CTL group as reflected by
main effect of treatment that just missed significance (p= 0.066).
In the analysis of SD rats, DES group did not differ from other
treatment groups when the drug administration was discontin-
ued; suggesting that enhanced avoidance following DES treatment
(E01–06) was not long-lasting.
Within-session avoidance responses are as averaged across early
(E01–03), mid (E04–06), or late (E07–09) extinction sessions.
Within-session analysis demonstrated that avoidance responses
decreased significantly in both strains with increasing trials in a
session, F(19,1368)= 23.07 (early, sessions E01–03), 46.45 (mid,
sessions E04–06), and 44.75 (late, sessions E07–09), ps< 0.001
(Figure 2B). CTL WKY rats exhibited significantly higher avoid-
ance responses compared to CTL SD rats throughout mid and
late sessions indicating slower within-session extinction in WKY
rats without drug treatment, F(3,72)= 4.89 (mid) and 4.00 (late),
ps< 0.005 and 0.05, respectively, post hoc ps< 0.05. However, in
both strains, drug treatment affected avoidance responding dif-
ferently in early, mid and later session-blocks. In WKY rats, BUP
and DES significantly facilitated within-session extinction dur-
ing early, middle, and late phases of extinction compared to CTL
(early: treatment× trial interaction, F(57,684)= 1.47, p< 0.05;
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FIGURE 3 | Non-reinforced responses (ITRs). ITRs within each 1-min
window are depicted in separate panels. More ITRs were performed during
the ITI-first minute compared to the ITRs performed during the ITI-second
and ITI-third minute regardless of strain or treatment. (A) During early
acquisition, WKY rats emitted more ITRs than SD rats, and more ITRs
compared to late acquisition sessions. However, SD rats emitted relatively
constant numbers of ITRs during the ITI-first minute as acquisition
proceeded and more ITRs during ITI-second and -third minute windows in
mid acquisition sessions. (B) During extinction, DES facilitated ITRs
selectively in SD rats across all three ITI windows compared to CTL. None
of the treatments affected ITRs in WKY rats regardless of ITI windows. Each
data point represents group mean±SEM. (n=8/treatment group, 16/CTL
group). Gray shade on x -axis indicates sessions in which drugs were
administered (E01–06).
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FIGURE 4 | Lever-press during the first minute of each session [i.e.,
anticipated response (AR)] in SD and WKY rats. (A) During the
acquisition phase, WKY rats emitted more ARs than SD rats. Both strains
increased ARs as acquisition continued. (B) During the extinction phase,
the ARs did not change as extinction continued regardless of strain or
treatment. However, during late extinction sessions (E07–09), DES-treated
SD rats emitted more ARs than the other SD groups. Each data point
represents group mean±SEM (n= 8/treatment group, 16/CTL group).
Gray shade on x -axis indicates sessions in which drugs were administered
(E01–06).
middle:F(3,36)= 4.31,p< 0.05; late:F(57,684)= 1.75,p< 0.001.
More over, first trial avoidance was not altered regardless of treat-
ment, suggesting between-session extinction may not be apparent
measured by first trial avoidance. In SD rats, none of the drugs
affected avoidance response in early extinction sessions. However,
in mid and late phases of extinction, DES impaired within-session
extinction (enhanced avoidance responding) compared to the
other treatments [middle: main effect of treatment, F(3,36)= 5.0,
p< 0.005, and treatment× trial interaction, F(57,684)= 1.51,
p< 0.05, post hoc ps< 0.05; late: treatment× trial interaction,
F(57,684)= 1.45, p< 0.05, post hoc ps< 0.05]. Neither BUP nor
PAR significantly altered within-session extinction in SD rats.
Non-reinforced responding
Anticipated responses decreased during the extinction phase,
F(8,573)= 2.09, p< 0.05 (Figure 4B). Notwithstanding that ARs
in WKY rats were not affected by any drug treatment, DES treat-
ment increased lever-presses compared to CTL treatment in SD
rats,F(3,36)= 3.11,p< 0.05,post hoc p< 0.05. On the other hand,
fewer lever-presses were emitted by all rats in each minute of the
ITI as extinction proceeded as reflected by main factor of Session,
F(8,573)= 31.5 (ITI-first minute), 26.25 (ITI-second minute),
and 29.78 (ITI-third minute), respectively,ps< 0.001 (Figure 3B).
More ITRs were emitted during the ITI-first minute compared to
responses emitted during the second and third minute regardless
of strain or treatment. In WKY rats, DES-treated rats emitted fewer
ITRs than CTL-treated peers, F(24,285)= 2.47 (ITI-first minute),
1.89 (ITI-second minute), and 1.76 (ITI-third minute), ps< 0.05,
post hoc,ps< 0.05. In contrast, DES treatment in SD rats enhanced
ITRs compared to the other treatments, F(3,36)= 3.07 (ITI-first
minute), 6.40 (ITI-second minute), and 5.14 (ITI-third minute),
ps< 0.05, post hoc, ps< 0.05.
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DISCUSSION
Avoidance and its perseveration represent key features of anxi-
ety disorders. Pharmacological approaches that reduce avoidance
behavior could facilitate recovery in patients with anxiety dis-
orders. The present study used an animal model of behavioral
inhibition, a risk factor for anxiety disorders, to test the effective-
ness of pharmacological intervention on preservative avoidance
behavior. WKY rats exhibited facilitated acquisition and delayed
extinction of lever-press avoidance compared to SD rats, consis-
tent with our previous reports (Servatius et al., 2008; Beck et al.,
2010, 2011; Jiao et al., 2011a). Moreover, drugs targeting distinct
monoamine systems affected extinction learning differently and
in a strain-dependent manner. BUP and DES significantly facili-
tated extinction of avoidance selectively in WKY rats while none
of the drugs enhanced extinction learning in SD rats. Instead, DES
impaired extinction learning in SD rats by increasing avoidance
responding. These data suggest that drugs can facilitate extinc-
tion of avoidance response selectively in animals with innate
vulnerability to anxiety.
In addition, the sensitivity to pharmacological manipulations
was not necessarily similar between different behavioral measures.
For instance, BUP and DES reduced avoidance responses in WKY
rats without affecting ARs or ITRs. In SD rats, DES not only
increased avoidance response but also enhanced ITRs. Despite the
fact that AR, ITR, and avoidance responding during extinction
all constitute non-reinforced behaviors, the results suggest that
these behaviors may be under different neurochemical CTL and
that pharmacological treatment could be designed to selectively
alleviate psychopathological avoidance and leave other behavioral
features intact to reduce side effects.
The results of the present study provide important informa-
tion regarding the neurobiological mechanisms of extinction of
avoidance behavior. Several neurochemical pathways have been
implicated in the development of anxiety and its neuropsy-
chopharmacology, while the neural mechanism of avoidance and
its extinction is far less understood. Converging literatures demon-
strate that an aberrant DA circuitry and (or) defective noradren-
ergic function is associated with anxiety disorders (Mathew et al.,
1981; Hamner and Diamond, 1996; Ballenger, 2001). Early studies
on the neurobiology of active avoidance also focused on cate-
cholamine systems (Beer and Lenard, 1975; Ashford and Jones,
1976; Fibiger and Mason, 1978; Oei and King, 1978; Raskin et al.,
1983; Koob et al., 1984). In general, DA has mostly been implicated
in the acquisition and expression of avoidance responses (Lenard
and Beer, 1975; Fibiger and Mason, 1978) while NE may be more
involved in the extinction of such responses (Lenard and Beer,
1975; Fibiger and Mason, 1978; Raskin et al., 1983). However,
selective lesions that targeted either the DA or NE system have
yielded inconsistent results. For instance, NE depletion did not
appreciably alter avoidance learning, but rather led to impairment
of extinction (Lenard and Beer, 1975; Fibiger and Mason, 1978),
while mice that lacked NE extinguished more rapidly compared
to intact CTLs (Thomas and Palmiter, 1997). The inconsistent
effects of lesions may be due to different lesion procedures and
compensatory mechanisms after lesion.
Extinction deficiency has been associated with malfunction
of various brain regions, especially the medial prefrontal cortex
(mPFC) and amygdala. The evidence is mainly obtained from
fear extinction paradigms. Hypoactive mPFC and hyperactive lim-
bic system, including nucleus accumbens (NAc) and amygdala,
are susceptibility factors in psychopathology of anxiety disorders
(Milad et al., 2006; Rauch et al., 2006). Historically, dysfunctional
catecholamine transmission in the mPFC and NAc has been asso-
ciated with abnormal active-avoidance behavior and implicated in
anxiety pathology (Giorgi et al., 1994; Duncan et al., 1996; Lacroix
et al., 1998; Weiss et al., 2001). However, results in rodents are
inconsistent due to the wide variety of animal models, behav-
ioral procedures and techniques employed. Here we utilized (1)
pharmacological agents that modulate NE, DA, and 5-HT neuro-
transmission in the brain by blocking corresponding transporters
in order to identify their role in extinction of avoidance and
(2) a unique rat model, the WKY rat strain that exhibits innate
abnormalities in DA and NE systems.
In the present study, DES, a tricyclic antidepressant that
increases synaptic NE level, facilitated extinction in WKY rats
after 2 weeks of treatment. In previous studies, increased locomo-
tion in OFT and swimming time in FST were reported following
DES treatment in WKY rats (Lopez-Rubalcava and Lucki, 2000;
Tejani-Butt et al., 2003). Thus, the present results with those
obtained previously suggest that blocking NET can ameliorate
anxiety- and depression-like behaviors in the WKY rat. WKY
rats exhibit higher NE transporter (NET) binding in hippocam-
pus and amygdala compared to SD rats, and repeated exposure
to novel stressors reduced β- and α2-adrenergic receptors selec-
tively in WKY rats, suggesting a pre-existing vulnerability to stress
is associated with malfunctions in noradrenergic system (Tejani-
Butt et al., 1994). In the present study, the 2 mA foot-shock during
acquisition may function as repeated physical stressors, while the
context and the warning signals may function as repeated psycho-
logical stressors; both could alter NET and receptor function in
WKY rats, which could lead to exaggerated avoidance response.
DES exerts its pharmacological effects via inhibition on NET and
auto-receptor desensitization in rats (Sacchetti et al., 2001; Zhao
et al., 2008; Zhang et al., 2009). Chronic DES treatment (i.e., more
than 10 days) not only reduces NET binding, but also alters β- and
α-adrenergic receptor binding in a region-specific manner in rats
(Hancock and Marsh, 1985; Zhao et al., 2008; Zhang et al., 2009).
Treatment with DES at the same dose that altered NE receptor and
NET (i.e., 10 mg/kg/day) blocked stress – and alcohol-induced
anxiety-like behavior in WKY rats (Durand et al., 2000; Getachew
et al., 2008). Thus, DES administration was expected to improve
extinction in WKY rats,possibly through pharmacological changes
in the NE system. In contrast, the same treatment appeared to
retard avoidance extinction in SD rats. The differential effects of
DES on avoidance response in the two strains could be attrib-
uted to different innate noradrenergic function. DES-treated SD
rats also emitted more non-reinforced response (i.e., ITRs) dur-
ing extinction, suggesting the retardation of avoidance extinction
may be due to elevated general locomotor activity, which has also
been reported previously following DES treatment (Maj et al.,
1987; Tejani-Butt et al., 2003). Thus, altering NE function could
yield different outcomes depending upon baseline NE activity and
individual variability in noradrenergic system following chronic
drug administration.
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Here, we also report that BUP, a selective DAT blocker and
a weaker NET blocker with antagonism of adrenergic receptors
and acetyl cholinergic receptors (Carroll et al., 2014), facilitates
extinction of active-avoidance selectively in the WKY strain. These
effects of BUP may be related to the fact that WKY rats have an
altered DA system associated with the distribution of transporter
and receptors in the brain (Jiao et al., 2003, 2006; Yaroslavsky
et al., 2006; Novick et al., 2008; Yaroslavsky and Tejani-Butt, 2010).
Given the role of the mesolimbic DA system in cognitive, emo-
tional, and motivational behaviors, we previously examined the
distribution of DAT sites in the brains of WKY compared to Wis-
tar (WIS) and SD rats and reported that WKY rats exhibited a
differential pattern of distribution of DAT binding sites in termi-
nal field regions versus the cell body areas in comparison to WIS
and SD rats (Jiao et al., 2003). At the time, we speculated that
the observed differences in the density and distribution of DAT
sites in WKY rats may lead to altered modulation of synaptic DA
levels in the cell body and mesolimbic regions and contribute to
behavioral differences previously observed. In terms of the role of
DA in active avoidance, the results are not clear and may depend
on which region investigated. NAc DA depletion leads to a sub-
stantial reduction in learning to lever-press to avoid or escape a
shock (McCullough et al., 1993), while mPFC 6-OH-DA lesions,
which reduce DA level to 13% of the CTL levels, do not affect
avoidance responding (Koob et al., 1978; Sokolowski et al., 1994).
Although the involvement of DA in the extinction of active avoid-
ance is unknown, DA in mPFC and amygdala is actively involved
in extinction of conditioned fear in rodents through modulation
of GABAergic neurons in the intercalated cell cluster (ITC) of
amygdala and basolateral amygdala (Morrow et al., 1999; Fernan-
dez Espejo, 2003; de la Mora et al., 2010; Rey et al., 2014). WKY
rats exhibit slower extinction of lever-press avoidance and lower
mPFC activity and amygdalar GABAergic activity compared to
SD rats (Jiao et al., 2011a), suggesting dysfunctional DA transmis-
sion in mPFC and amygdala could be the possible mechanisms.
Repeated treatment with DAT blockers (i.e., BUP and nomifen-
sine) not only increases DAT levels in mesolimbic regions (Jiao
et al., 2006) but also facilitates extinction learning (in the present
report) and reduces anxiety-like behavior in the OFT (Tejani-Butt
et al., 2003), further supporting that DA is playing a critical role
in modulating emotion and responses associated with aversive
stimuli.
Nucleus accumbens, a heavily DA-innervated limbic area, is
another region of interest involved in BUP-associated effects
because of its role in motivated behavior and emotion (Koob,
1992; Ahn and Phillips, 2007). Higher DA turnover rate and recep-
tor binding combined with lower DAT binding in the NAc leads to
elevated DA activity in the NAc in WKY rats (Jiao et al., 2003; De La
Garza and Mahoney, 2004; Novick et al., 2008; Scholl et al., 2010),
and this condition is often associated with increased emotionality
and greater avoidance responding (Ikemoto and Panksepp, 1999).
In the present study, BUP administration accelerated extinction
in WKY rats, supporting a positive DA involvement in extinction
learning. Moreover, PFC DA is important for cognitive processes
such as decision-making and avoidance, but PFC has very low
DAT distribution in rats and the reuptake of DA in this region
mainly relies on NET (Wayment et al., 2001; Moron et al., 2002).
Therefore, both DES and BUP may elicit similar effects (i.e.,
increased synaptic DA and NE levels) within PFC, which is a pos-
sible mechanism underlying their similar effects on extinction in
WKY rats.
The role of 5-HT in avoidance is less clear. Earlier pharmaco-
logical studies using one-way avoidance in shuttle box demon-
strated that increased 5-HT transmission is associated with a
deficit in acquisition and retention and decreased 5-HT leads to
facilitated acquisition through the hippocampus and prefrontal
cortex (Ogren, 1986a,b). However, pharmacological agents that
facilitate serotonin transmission either impaired passive avoid-
ance and facilitated its extinction (Shugalev et al., 2008) or had
no effect on a two-way avoidance task (Sun et al., 2010) in rats.
Moreover, chronic fluoxetine treatment reverses generalized avoid-
ance in a mouse model of post-traumatic stress disorder (PTSD)
(Pamplona et al., 2011), suggesting serotonergic agents modu-
late avoidance and its extinction via influencing the emotional
response. Thus, serotonergic agents seem to be in a good posi-
tion to alter behavioral abnormalities such as persistent avoidance.
Most importantly, although SSRIs are the first line medication
to treat anxiety symptoms, they are found to be ineffective in
many patients (Pollack et al., 2006, 2008). Similar to those SSRI
refractory cases, WKY rats do not respond to chronic SSRI treat-
ment measured by OFT or FST at baseline condition or follow-
ing stress challenge (Sanchez and Meier, 1997; Durand et al.,
1999; Lopez-Rubalcava and Lucki, 2000; Tejani-Butt et al., 2003;
Rosenzweig-Lipson et al., 2007). Here, we observed that PAR facil-
itated within-session extinction learning in WKY rats only in
the mid extinction sessions; however, both BUP and DES facili-
tated within-session extinction in early, mid, and late extinction.
Moreover, WKY rats treated with PAR appeared to resume avoid-
ance responses in extinction sessions in which the drug was not
on board. Therefore, the WKY rat may be a useful model for
SSRI-resistant anxiety.
We also found that PAR, at a dose that is effective in reducing
stress-induced abnormalities in OFT/FST in SD rats (Tejani-Butt
et al., 2003), did not change avoidance responding in SD rats in the
present study. This discrepancy could be due to different behav-
ioral procedures and paradigms used in previous studies and the
present study. Previously, relatively short behavioral tests such as
OFT and FST were used to evaluate emotional response follow-
ing various durations of stress period (i.e., acute versus 7 days to
weeks of chronic stress). Here, we trained rats to acquire lever-
press avoidance using foot-shock for 12 sessions and each session
lasted for over an hour depending on performance. This paradigm
allows the development of effective coping mechanisms in normal
rat strains but promotes avoidance perseveration in rats that are
vulnerable to stress, such as the WKY strain (Jiao et al., 2011a).
Therefore, the lack of effect in SD rats following PAR treatment
here may be explained by normal coping behaviors being more
resilient to pharmacological intervention due to homeostasis in
brain neurochemistry. However, the possibility that a higher dose
may have facilitated avoidance extinction can not be ruled out
since only a single dose was tested in the present study. Thus, our
findings of the distinctive role of monoamine in avoidance behav-
ior will, hopefully, shed a light on the neurochemical mechanisms
underlying anxiety disorders.
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Anticipated responses are often associated with fear and anx-
iety disorders in humans and experimental animals (Conrod,
2006; Bailey and Crawley, 2009; Straube et al., 2009). However,
whether and how this behavioral feature responds to pharmaco-
logical manipulation has not been thoroughly studied. Consistent
to our previous report (Perrotti et al., 2013), here we found that
WKY rats exhibited more ARs during acquisition compared to SD
rats, suggesting a positive relationship between ARs and avoidance-
prone behavior. However, this strain difference disappeared during
extinction in CTL-treated WKY and SD rats, suggesting ARs may
be labile depending on environmental factors (i.e., both foot-shock
and the flashing light were removed during extinction). In addi-
tion, none of the agents significantly altered ARs in drugged groups
compared to CTL groups, regardless of strain. The present data
provide little support to associate ARs with avoidance persever-
ation. However, evaluating ARs in anxiety is beyond the scope
of this study since we only measured lever-press as the main
response to evaluate AR. Physiological and autonomic responses
such as skin conductance and heart beat may be more appropriate
to study anticipatory responding. In the future, these measure-
ments may be used to better characterize pharmacological effects
on ARs.
Lastly, we believe that the effects of the agents used in the
present study are due to chronic pharmacodynamics changes at
transporter and receptor levels instead of neurochemical con-
centration changes at synaptic level. Given that all three agents
have relatively short half-lives in rat brain tissue, from 5 h (PAR)
to 8 h (DES) (Suckow et al., 1986; Caccia et al., 1993; Cox
et al., 2011), we treated animals over 12 h before the start of
the first post-treatment extinction session. Moreover, other post-
treatment extinction sessions occurred days and weeks after the
last administration, which provides sufficient clearance to elu-
cidate non-drug effect on extinction. Further examination of
neuronal activation in limbic regions will provide direct evi-
dence illustrating how these agents affect avoidance behavior in
both strains. On the other hand, only one dosage for each agent
was used in this study. Although SSRIs have a relative flat dose–
response curve to treat social anxiety disorder and fixed-dose
of SSRIs has been used as a standard treatment strategy, clini-
cal evidence suggests that optimal effect may be obtained with
higher doses of SSRI (van der Linden et al., 2000; Baker et al.,
2003; Lader et al., 2004). Thus, the lack of effectiveness of PAR
in extinction training may reflect an insufficient dose used in
WKY rats.
In summary, this study examined the effects of three classes
of psychotropic agents commonly used in treating anxiety and
depression-like symptoms in humans on extinction of a lever-press
active-avoidance task in rats. Given the behavioral, neurochemical,
and pharmacological features demonstrated in the WKY rat, NET,
and DAT inhibitors were more effective in facilitating extinction
of avoidance behaviors but SSRIs was the least effective. Thus, the
WKY rat could be used as a powerful tool to examine novel treat-
ment targeting anxiety symptoms in patient population that is
resistant to conventional SSRI treatment. Similar to the enhanced
prevalence of anxiety disorder in females (Pigott, 2003), we have
reported that female SD rats are more sensitive to learn avoid-
ance than male SD rats, while female and male WKY rats learn
avoidance to similar degrees (Beck et al., 2011). It would be impor-
tant to assess the effects of monoaminergic drugs on female rats
in the future.
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